Novartis Ends Mid-Stage Fabhalta Trial Targeting Serious Kidney Condition

Novartis abandons Fabhalta trial in lupus nephritis

A failed phase 2 study has undermined Novartis' hopes of extending the approved indications for Fabhalta to include lupus nephritis.

Novartis ends mid-stage Fabhalta trial targeting serious kidney condition - Regional Media News

Oct 16 (Reuters) - Swiss drugmaker Novartis has terminated a mid-stage study testing its drug Fabhalta in patients with a serious kidney condition, citing "strategic considerations", according to a federal clinical trials registry. • The trial was evaluating whether the oral medication was safe and effective for treating lupus nephritis when added to standard medical care • Lupus nephritis is a severe inflammation of the kidneys caused by the au…

Novartis halts mid-stage trial for kidney drug, Fabhalta (NVS)

Novartis (NVS) ends a mid-stage trial for kidney drug Fabhalta (iptacopan) in lupus nephritis because of strategic considerations. Read more here.

Novartis ends mid-stage Fabhalta trial targeting serious kidney condition

Oct 16 (Reuters) - Swiss drugmaker Novartis has terminated a mid-stage study testing its drug Fabhalta ​in patients with a serious ‌kidney condition, citing "strategic considerations", according to a federal clinical trials registry. • The trial was ev...

Novartis Ends Phase 2 Fabhalta Trial for Lupus Kidney Disease

In an Oct. 15 update, Novartis gave strategic considerations as the reason after Part 1’s final patient completed the last visit.

Novartis scraps Fabhalta study in lupus nephritis

Novartis terminated a mid-stage trial of Fabhalta in lupus nephritis, citing “strategic considerations,” according to a federal clinical trials database. Fabhalta, also known as iptacopan, is a key part of Novartis' portfolio. It delivered $505 ...